NCYT:LON
Novacyt SA
GBX 39,20
arrow_downward
-1,01%(-0,40) 1D
16 ຕ.ລ., 13 ໂມງ 44 ນາທີ 07 ວິນາທີ GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NCYT...
Open
GBX 39,60
High
GBX 39,68
Low
GBX 39,20
Mkt. cap
33,77 ລ້ານ
Avg. vol.
102,63 ພັນ
Volume
6,85 ພັນ
52-wk high
GBX 86,00
52-wk low
GBX 26,60
Shares outstanding
37,66 ລ້ານ
No. of employees
228
Open
GBX 39,60
High
GBX 39,68
Low
GBX 39,20
Mkt. cap
33,77 ລ້ານ
Avg. vol.
102,63 ພັນ
Volume
6,85 ພັນ
52-wk high
GBX 86,00
52-wk low
GBX 26,60
Shares outstanding
37,66 ລ້ານ
No. of employees
228
News stories
From web sources and news partners
Quiver Quantitative
·
35 ນາທີກ່ອນ
Private Bancorp of America Reports Third Quarter 2026 Net Income of $11.4 Million and Diluted EPS of $1.97 as Deposits and Loans Grow After NASDAQ Uplisting
The Daily News | Texas' Oldest Newspaper
·
45 ນາທີກ່ອນ
FILE PHOTO: Signage is seen outside the New York Stock Exchange (NYSE) in Manhattan, New York City
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA